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Abstract
The aim of this analysis of historical data was to determine whether patients’ pre-treatment beliefs about antiretroviral therapy 
(ART) predict the subsequent reporting of side effects. Data were collected as part of a prospective, 12-month follow-up 
study. Of 120 people starting ART, 76 completed follow-up assessments and were included in the analyses. Participants 
completed validated questionnaires assessing their beliefs about ART, beliefs about medicines in general, perceived sensi-
tivity to adverse effects of medicines, depression and anxiety before initiating ART and after 1 and 6 months of treatment. 
Adherence was assessed at 1, 6 and 12 months. Pre-treatment concerns about ART were associated with significantly more 
side effects at 1 month (p < 0.05) and 6 months (p < 0.005). Side effects at 6 months predicted low adherence at 12 months 
(p < 0.005). These findings have implications for the development of interventions to support patients initiating ART by 
providing a mechanism to pre-empt and reduce side effects.
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Resumen
El objetivo de este análisis de datos históricos fue determinar si las creencias de los pacientes sobre el tratamiento antirretro-
viral (TAR) predecían la declaración posterior de efectos secundarios. Los datos fueron recogidos como parte de un estudio 
prospectivo de 12 meses. De las 120 personas que comenzaron el TAR, 76 completaron las evaluaciones de seguimiento y 
se incluyeron en los análisis. Los participantes respondieron a cuestionarios validados que evalúan sus creencias sobre el 
TAR, creencias sobre los medicamentos en general, la sensibilidad percibida ante los efectos adversos de los medicamen-
tos, la depresión y la ansiedad antes de iniciar el TAR y transcurridos 1 y 6 meses de tratamiento. La adherencia al TAR se 
evaluó a 1, 6 y 12 meses. Las preocupaciones previas al inicio del tratamiento acerca del TAR se asociaron con un número 
significativamente mayor de efectos secundarios al cabo de 1 mes (p < 0.05) y 6 meses (p < 0.005). Los efectos secundarios 
a los 6 meses predijeron baja adherencia a los 12 meses (p < 0.005). Los resultados de este análisis tienen implicaciones 
en el desarrollo de intervenciones para apoyar a los pacientes que comienzan el TAR, proporcionando un mecanismo para 
adelantarse y reducir los efectos secundarios.
Introduction
Antiretroviral therapy (ART) extends life expectancy, 
improves quality of life and prevents transmission of HIV 
[1–3]. Compared with first generation ART, newer agents 
have been associated with a lower incidence of treatment-
limiting side effects, such as liver toxicity and changes in 
fat distribution. However non-specific side effects such 
as fatigue and nausea are still frequently reported [4, 5]. 
Although there is often no recognised pharmacological 
explanation, these side effects cause distress and impair 
quality of life [5]. Moreover, side effects are among the most 
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common reasons for treatment switches and nonadherence 
to ART [6, 7] and therefore contribute to suboptimal treat-
ment outcomes.
Side effects are commonly defined as the action of a drug 
other than the one intended. However, not all side effects can 
be directly attributed to the pharmacological action of the 
drug. Many patients experience side effects when taking pla-
cebo [8], indicating that side effects can be caused by factors 
other than the drug itself. These negative, nonspecific effects 
of a drug are described as nocebo responses [9]. Factors such 
as verbal suggestion and negative treatment experiences can 
induce side effects in people taking both placebos and active 
drug treatment [10, 11]. A better understanding of the deter-
minants of side effects of ART could help healthcare profes-
sionals to identify patients who are at risk of developing side 
effects and offer appropriate support.
Beliefs about medicines are reliable predictors of ART 
nonadherence and discontinuation [12–14]. Studies in other 
long-term conditions have found associations between 
patients’ beliefs about treatment and their experience of 
side effects. For example, patients’ pretreatment expecta-
tions of side effects from cancer treatments predicted the 
subsequent reporting of side effects [15, 16]. Concerns about 
medicines have been associated with side effects both in 
cross-sectional studies of Medicaid enrolees [17, 18] and in 
a prospective study, where heightened concerns about treat-
ment for rheumatoid arthritis independently predicted side 
effects 6 months later [19]. Patients who perceived them-
selves to be particularly sensitive to adverse effects from 
medicines were more likely, than people without this belief, 
to report symptoms in the week following vaccination [20]. 
Negative affect and trait anxiety have also been found to 
predict side effects [16, 20].
Little is known about psychological determinants of side 
effects in people taking ART. A cross-sectional study found 
that patients’ concerns about ART were associated with a 
greater number of symptoms reported by patients, but due to 
the cross-sectional design of the study it was not possible to 
determine whether experiencing symptoms led to treatment 
concerns, or whether pre-existing concerns about ART led 
to a greater number of symptoms [14]. Furthermore, it was 
not clear whether patients attributed the symptoms to HIV, 
ART or another cause.
To our knowledge, no studies to date have evaluated 
whether specific and general medication beliefs, or other 
psychological factors such as depression and anxiety, pre-
dict side effect reports in HIV. We therefore set out to 
explore this in historical data from a prospective study 
conducted from 2000 to 2004 which measured patients’ 
beliefs about medicines, experiences of side effects, 
depression, anxiety and adherence to ART over the first 
12 months of a new ART regimen. Since specific medi-
cation concerns are often related to more general beliefs 
about pharmaceuticals and perceptions of personal sen-
sitivity to the effects of medicines (collectively known 
as ‘pharmaceutical schema’ [21]), we explored whether 
patients’ beliefs about medicines in general and perceived 
sensitivity to medicines were associated with concerns 
about ART. We believe that the use of historical data is 
appropriate to address this question despite advances in 
antiretroviral regimens and side effect profiles, because 
the question of whether beliefs about medicines predict 
the reporting of side effects is not dependent on the type 
of side effects reported.
Methods
This analysis was conducted using data collected as part of 
a prospective study of uptake and adherence to ART among 
HIV positive patients attending the Lawson Unit, a National 
Health Service (NHS) HIV clinic in Brighton, United King-
dom (for further details see [12]). Patients completed ques-
tionnaires before initiating ART (baseline) and after 1 and 
6 months. Self-reported adherence was measured at 1, 6 and 
12 months.
Participants
Patients were eligible for the study if they were HIV posi-
tive, attending the Lawson Unit, and not taking antiretroviral 
therapy. Participants who subsequently accepted a clinically 
indicated offer of ART formed the study sample and were 
followed up for a year. Exclusion criteria were having insuf-
ficient understanding of English or being too ill to complete 
the study questionnaires.
Procedure
Consecutive study-eligible individuals were referred to the 
study by their HIV doctor. Standard procedures for obtain-
ing written informed consent were followed. Researchers 
attended weekly multidisciplinary meetings to identify 
patients who were eligible for an offer of ART based on con-
temporaneous British HIV Association (BHIVA) treatment 
guidelines [22]. Following a treatment recommendation, 
participants were given a questionnaire to complete along 
with a stamped addressed envelope for its return. Medical 
notes and pharmacy records were consulted to identify par-
ticipants who initiated ART. These participants were sent 
follow-up questionnaires after 1, 6 and 12 months. Tele-
phone reminders were administered to optimise response 
rates.




ART side effects were measured using an adapted version 
of the Identity subscale of the Illness Perceptions Question-
naire-Revised (IPQ-R) [23]. The original IPQ-R has been 
validated across multiple illness groups [23]. The IPQ-R 
symptoms scale comprises 11 core symptoms common to 
a variety of illnesses. We modified the scale for this study 
by adding 12 common HIV/ART related symptoms. Par-
ticipants were asked to indicate which if any of the symp-
toms they experienced as a result of taking ART. If they 
had experienced the symptom they were asked to rate the 
severity of the symptom on a scale of 1–5, where 1 = very 
mild, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe. 
To ensure that only symptoms that were problematic to the 
patient were included, we counted the number of symptoms 
that the participants rated as moderate, severe or very severe 
(scored 3–5). This gave a possible score of 0–23, represent-
ing the number of symptoms that the participant perceived 
to be moderate, severe or very severe.
Beliefs About Medicines
Beliefs about medicines were measured using the Beliefs 
about Medicines Questionnaire (BMQ) [24, 25]. We 
used both General and Specific versions—the BMQ-
General, assesses beliefs about medicines as a whole, 
and the BMQ-Specific, assesses beliefs about a specific 
prescribed medicine. The BMQ-General compares three 
subscales, each consisting of 4 items. The General Harm 
scale assesses beliefs that medicines are harmful, addic-
tive poisons; the General Overuse scale assesses beliefs 
that medicines are overused by doctors, and General Ben-
efits scale assesses beliefs that medicines generally are 
beneficial. Scores for individual items within each scale 
were summed. A mean score was computed by dividing 
each total score by the number of items, giving a range 
of 1–5 for each scale. Beliefs about ART were measured 
using the BMQ-Specific-ART specific version (BMQ-
ART) [12, 24] which has previously been validated in 
people living with HIV [26]. The BMQ-ART comprises 
two scales: an ART-Necessity scale consisting of 6 items 
assessing participants’ perceptions of their personal need 
for ART for controlling HIV and maintaining health, and 
an ART-Concerns scale, consisting of 7 items assessing 
concerns about potential adverse consequences of ART 
(e.g. concerns about short and long-term effects and 
the concern that taking ART would disrupt daily life). 
Participants were presented with a series of statements 
and asked to rate their level of agreement with each on 
a scale where possible responses ranged from strongly 
agree to strongly disagree. After reverse scoring relevant 
items, scores for individual items within each scale were 
summed. A mean score was computed by dividing each 
total score by the number of items, giving a range of 1–5 
for both Necessity and Concern scales, with higher scores 
representing stronger necessity beliefs and concerns.
Perceived Sensitivity to Medicines (PSM) Scale
Participants rated 5 items concerning their body’s response 
to medicines on a 5-point Likert scale anchored from 
‘strongly agree’ to ‘strongly disagree’ [27]. Individual item 
scores were summed to provide a total PSM score ranging 
from 5 to 25. In order to facilitate comparison of scores 
between scales, a mean score was computed by dividing 
by the number of items, giving a range of 1–5. The PSM 
scale has been shown to have adequate reliability and valid-
ity [27].
Hospital Anxiety and Depression Scale (HADS)
The HADS is a brief measure of state anxiety (7 items) 
and depression (7 items) which was developed to deter-
mine clinical anxiety/depression and determine the sever-
ity of symptoms in patients attending outpatient clinics, 
without contamination of scores by reporting of physical 
symptoms. There was no overlap between the items on the 
HADS and the items included on our measure of ART side 
effects. Items were scored from 0 to 3 according to a scoring 
manual. Possible scores range from 0 to 21. Higher scores 
indicate greater anxiety or depression. Scores of 8–10 in 
each subscale indicate possible clinical disorder, scores of 
11–21 indicate probable clinical disorder. The HADS has 
demonstrated good psychometric properties in studies of 
medical outpatients [28].
Adherence
Adherence to ART was measured using a visual analogue 
scale (VAS) from the Medication Adherence Self-Report 
Inventory (MASRI) [29]. The MASRI is worded in a non-
judgmental manner in an effort to minimize socially desir-
able responses. The VAS has demonstrated good validity 
against objective measures (electronic monitoring: r = 0.63, 
p < 0.001; pill count: r = 0.75, p < 0.001; and viral load: 
p < 0.01) [29]. Participants were asked to estimate on a vis-
ual analogue scale from 0 to 100 the percentage of medica-
tion they had taken as prescribed over the previous month. 
Those who reported taking less than 95% of ART medicines 
were categorised into a low adherence group, and those tak-
ing 95% or more of their medication as prescribed were allo-
cated to a high adherence group. The 95% threshold was 
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chosen on the basis of research linking ≥ 95% adherence to 
undetectable viral load [30].
Clinical and Demographic Data
Clinical and demographic information, including age, sex, 
employment status, sexual orientation, number of years since 
first HIV diagnosis, symptom classification (asymptomatic 
HIV, symptomatic HIV or AIDS), whether the person had 
previously been prescribed ART, CD4 count and viral load 
 (log10) was extracted from participants’ medical records.
Analysis
Data were analysed using IBM SPSS Statistics 24. Clinical 
and demographic characteristics of the sample and question-
naire scores at baseline were compared between those who 
completed the study and those with missing data at 1 and 
6 months using χ2 tests for categorical data and independent 
samples t-tests for continuous variables. Cochran’s Q test 
was used to compare the number of participants reporting 
low adherence across 1, 6 and 12 months. Pearson’s cor-
relations were used to assess associations between clinical, 
demographic and psychological variables and (1) the num-
ber of moderate, severe or very severe side effects reported 
at 1 month and 6 months, and (2) baseline BMQ-Concerns 
scores. Point biserial correlations were reported where one 
variable was categorical. The BMQ-Concerns score was 
dichotomised into high concerns and low concerns by split-
ting the group on the median score.
In order to test the hypothesis that depression and anxiety 
mediate the relationship between concerns about ART and 
the subsequent reporting of side effects, we conducted medi-
ational analyses in line with the recommendations of Kenny 
[31, 32]. We hypothesised that ART concerns at baseline 
would be associated with anxiety and depression at 1 month, 
and that anxiety and depression at 1 month would mediate 
the relationship between baseline concerns and side effects 
at 6 months. This hypothesis was tested by using multilin-
ear regression analyses to assess relationships between the 
independent variable (ART-Concerns at baseline), the out-
come (side effects at 6 months) and the proposed mediators 
(depression or anxiety at 1 month). Multilinear regression 
analyses were used to control for the proposed mediators 
(depression and anxiety) when assessing the relationship 
between ART-Concerns and side effects.
Results
Four hundred and ninety-one patients were eligible for the 
study, and 365 (74.3%) were referred by their physician. 
Three hundred and twenty-two (88.2%) of those referred 
agreed to take part. After recruitment, 153 participants were 
recommended HAART and 136 (88.9%) returned question-
naires and were included in the original analysis [12]. Of 
those, 98 participants initially initiated treatment [12]. A 
further 22 participants enrolled in the study initially declined 
a treatment recommendation but initiated treatment over the 
1 year follow-up. A total of 120 participants were therefore 
eligible for the current study. Over the follow-up, 17 partici-
pants stopped treatment, 3 died, and 24 were lost to follow-
up, missed one or more follow-up or returned questionnaires 
with missing data. Seventy-six participants provided data 
at each time point and formed the sample for this study. 
Clinical and demographic characteristics of the sample are 
shown in Table 1.
ART Side‑Effects
At 1 month, 55 (72.4%) participants reported ≥ 1 moderate 
to severe symptom that they attributed to ART. The num-
ber of symptoms reported ranged from 0 to 17 (mean = 3.8, 
SD = 4.4). At 6 months, 45 (59.2%) participants reported ≥ 1 
moderate to severe symptom that they attributed to ART. 
The number of symptoms reported ranged from 0 to 17 
(mean = 3.2 SD = 4.4). The ten most common side effects 
reported at 6 months were sleep difficulties (29%), sexual 
problems (26%), fatigue (24%), skin problems (22%), diar-
rhoea (21%), altered sensation in hands or feet (18%), stiff 
joints (16%), nausea (16%), headaches (16%) and pain 
(15%).
Beliefs About Medicines
Mean scores and standard deviations for scales measuring 
beliefs about treatment at baseline are shown in Table 2. 
Table 2 also shows the percentage of participants scoring 
above the midpoint for each scale. This provides an esti-
mate of the proportion of participants who hold strong 
views about the construct measured by each scale. The vast 
majority (99%) of participants had strong views about the 
necessity of their treatment, however half the sample (51%) 
had strong concerns about potential adverse consequences 
of taking ART. Examination of individual items on the 
BMQ ART-Concerns scale showed that the most frequently 
endorsed concerns were worries about long-term effects and 
concerns about side effects. 58% of participants agreed or 
strongly agreed with the item “I would worry about the long-
term effects of this medicine” while 49% agreed or strongly 
agreed with the item “These medicines would give me 
unpleasant side effects.” Most participants had fairly positive 
beliefs about medicines in general, with 97% scoring above 
the scale mid-point on the BMQ-General Benefit scale and 
only 15% scoring above the midpoint on the BMQ-General 
Harm scale, however 53% scored above the mid-point on the 
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BMQ General Overuse scale. Almost a third of participants 
(32%) perceived themselves to be particularly sensitive to 
medicines in general as indicated by their responses to the 
PSM scale.
Anxiety and Depression
Scores on the HADS depression scale at baseline ranged 
from 0 to 19. The mean score was 5.3 (SD = 4.4). Fifty-one 
participants (67.1%) had scores in the range of 0–7, indicat-
ing the absence of clinically significant depression. A fur-
ther 17 (22.4%) participants had scores of 8–10 indicating 
possible clinical depression and 8 (10.5%) had scores of 11 
and above indicating probable clinical depression. Scores 
on the HADS anxiety scale at baseline ranged from 0 to 
19. The mean score was 7.5 (SD = 4.8). Thirty-nine par-
ticipants (51.3%) had scores in the range of 0–7, indicating 
the absence of clinically significant anxiety. A further 14 
participants (18.4%) had scores of 8–10 indicating possible 
clinical anxiety and 23 (30.3%) had scores of 11–21 indicat-
ing probable clinical anxiety.
Table 1  Sample demographics and clinical characteristics
BMQ beliefs about medicines in general, HADS hospital anxiety and depression scale, PSM perceived sensitivity to medicines scale
Baseline clinical/demographic feature Completed study n = 76 Missing data n = 44 p
Age (years) Mean (SD) 40.2 (8.8) 34.2 (6.2) t = − 4.00 < 0.001
Men who have sex with men (MSM) n (%) 70 (92.1) 38 (86.4) χ2 = 0.312 0.312
White British n (%) 23 (30.3) 21 (47.7) χ2 = 3.660 0.056
Employed n (%) 53 (69.7) 24 (54.5) χ2 = 2.797 0.094
Years since HIV diagnosis Mean (SD) 4.6 (5.1) 3.9 (4.2) t = 0.442 0.442
Asymptomatic HIV n (%) 24 (31.6) 13 (29.5) χ2 = 0.054 0.816
Symptomatic HIV n (%) 34 (44.7) 17 (38.6) χ2 = 0.424 0.515
AIDS n (%) 18 (23.7) 14 (31.8) χ2 = 0.943 0.332
Prior antiretroviral therapy n (%) 20 (26.3) 24 (54.5) χ2 = 9.563 0.002
CD4 count  (mm3/L) Mean (SD) 198.3 (119.3) 190.1 (145.2) t = 0.736 0.736
Viral load  (log10 copies/mL) Mean (SD) 5.3 (0.5) 5.3 (0.5) t = 0.953 0.605
BMQ-necessity Mean (SD) 4.0 (0.5) 3.7 (0.6) t = − 2.959 0.004
BMQ-concerns Mean (SD) 3.0 (0.6) 3.2 (0.6) t = 1.803 0.074
BMQ—general overuse Mean (SD) 3.0 (0.7) 3.1 (0.7) t = 0.795 0.428
BMQ—general harm Mean (SD) 2.4 (0.5) 2.7 (0.5) t = 2.652 0.009
BMQ—general benefits Mean (SD) 3.9 (0.5) 3.7 (0.4) t = − 1.689 0.095
PSM Mean (SD) 2.5 (0.7) 3.2 (1.1) t = 3.394 0.001
HADS depression Mean (SD) 5.3 (4.4) 7.2 (4.6) t = 2.192 0.030
HADS anxiety Mean (SD) 7.5 (4.9) 10.6 (4.9) t = 3.351 0.001
Table 2  Scale descriptives at 
the baseline assessment
BMQ beliefs about medicines questionnaire, PSM perceived sensitivity to medicines scale










6 0.839 4.0 0.5 98.7
BMQ ART-Con-
cerns
7 0.764 3.0 0.6 51.3
BMQ ART-Gen-
eral Harm
3 0.420 2.4 0.5 14.5
BMQ ART-Gen-
eral Overuse
4 0.660 3.0 0.6 53.2
BMQ ART-Gen-
eral Benefits
4 0.645 3.9 0.5 96.7
PSM 5 0.836 2.5 0.7 32.2
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Adherence to ART 
The number of participants reporting < 95% adherence 
increased from 5 (6.6%) at 1  month to 17 (22.4%) at 
12 months (Cochran’s Q = 20.32, df = 3, p < 0.001). Side 
effects at 6 months predicted non-adherence at 12 months: 
Participants with high adherence at 12 months reported 
a mean of 2.5 (SD = 3.9) side effects at 6 months, while 
those who reported low adherence at 12 months reported a 
mean of 5.8 (SD = 5.2) side effects at 6 months (t = − 2.905; 
p = 0.005). Side effects at 1 month did not significantly 
predict low adherence at 6 months or 12 months: partic-
ipants with high adherence at 6 months reported a mean 
of 3.65 (SD 4.34) side effects at 1 month while those who 
reported low adherence at 6 months reported a mean of 
4.50 side effects at 1 month (t = − 0.687; p = 0.494). Par-
ticipants with high adherence at 12 months reported a mean 
of 3.4 (SD = 4.2) side effects at 1 month, while those who 
reported low adherence at 12 months reported a mean of 5.5 
(SD = 4.5) side effects at 1 month (t = − 1.778, p = 0.080).
Baseline Predictors of Side Effects
Consistent with expectations, reporting of moderate to 
severe side effects at 1 month and 6 months was associ-
ated with BMQ ART-Concerns at baseline (Table 3; Fig. 1). 
Specific concerns about ART associated with side effects 
at 6 months are shown in Fig. 2. Side effects at 1 month 
and 6 months were also strongly associated with depression 
and anxiety scores on the HADS (Table 3). With the excep-
tion of duration of HIV, reporting of side effects at 1 and 
6 months was not associated with baseline demographic or 
clinical variables (age, previous ART prescription, diagnosis 
of AIDS, CD4 count, viral load  log10; Table 3).  
Determinants of ART Concerns
ART-Concerns at baseline were significantly associated with 
BMQ General-Harm beliefs, perceived sensitivity to medi-
cines, and symptoms of depression and anxiety (Table 4). 
ART-Concerns at baseline were not significantly associated 
with baseline demographic characteristics, previous experi-
ence of ART or any other clinical variable (Table 4).
Mediational analyses
In line with our hypothesis, BMQ  ART-Concerns at 
baseline was correlated with the outcome, side effects 
at 6 months (r = 0.360; p < 0.01). Also, BMQ ART-Con-
cerns at baseline was significantly correlated with the 
proposed mediators. anxiety and depression at 1 month 
(anxiety: r = 0.506; p < 0.0001; depression: r = 0.5318; 
p < 0.0001). Furthermore, anxiety and depression at 
1 month were correlated with side effects at 6 months 
(anxiety: r = 0.501; p < 0.0001; depression: r = 0.542; 
p < 0.0001). The mediation effect induced by anxiety 
and depression at 1 month was demonstrated through the 
construction of a model using linear regression equations 
Table 3  Baseline predictors 
of side effects at 1 month and 
6 months
BMQ beliefs about medicines in general, HADS hospital anxiety and depression scale
1 month 6 months
r or  rp p r or  rp p
Age r − 0.012 0.916 0.038 0.744
White British rp − 0.112 0.334 − 0.097 0.405
Men who have sex with men (MSM) rp 0.201 0.081 0.114 0.326
Employed rp − 0.197 0.088 − 0.184 0.112
AIDS diagnosis rp − 0.021 0.859 − 0.104 0.369
Prior antiretroviral therapy (ART) rp 0.216 0.061 0.114 0.325
Protease-inhibitor-based ART regimen rp − 0.722 0.474 − 0.013 0.990
CD4 count  (mm3/L) r 0.151 0.193 0.108 0.353
Viral load  (log10 copies/mL) r 0.103 0.378 0.144 0.216
Duration of HIV diagnosis (years) r 0.281 0.014 0.296 0.010
BMQ ART-Necessity r − 0.177 0.125 − 0.203 0.079
BMQ ART-Concerns r 0.347 0.002 0.360 0.001
BMQ ART-General Overuse r − 0.113 0.383 − 0.103 0.425
BMQ ART-General Harm r 0.201 0.116 0.178 0.166
BMQ ART-General Benefit r − 0.147 0.259 − 0.144 0.267
Perceived Sensitivity to Medicines (PSM) r 0.262 0.045 0.241 0.066
HADS Depression r 0.403 0.000 0.450 < 0.001
HADS Anxiety r 0.454 0.000 0.440 < 0.001
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where anxiety and depression at 1 month were respec-
tively taken as a criterion variable and ART concerns 
at baseline as a predictor, and a multilinear regression 
equation taking side effects at 6 months as the criterion 
variable and BMQ ART-Concerns at baseline and anxi-
ety and depression at 1 month as predictors (F = 10.850; 
df = 3; p < 0.001). Applying Baron and Kenny’s equation 
[32] to assess whether depression and anxiety at 1 month 
Fig. 1  Mean number of moder-
ate, severe or very severe side 
effects reported at 1 month and 
6 months by patients with high 
concerns and those with low 
concerns at baseline
Fig. 2  Mean number of moderate, severe or very severe side effects reported at 6 months by patients endorsing each of the BMQ ART-Concerns 
items at baseline
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mediate the relationship between the causal variable (ART 
concerns at baseline), and the outcome (side effects at 
6 months), resulted in ratio of 0.78. Since the size of the 
indirect effect was < 0.80 [32], this suggests that anxiety 
and depression at 1 month partially mediate the relation-
ship between baseline ART-Concerns and side effects at 
6 months.
Discussion
This is the first study to demonstrate that beliefs about 
medicines predict subsequent reporting of ART side-
effects. Patients’ concerns about ART at the time of the 
treatment recommendation influenced their subsequent 
experience of side effects. Side effects were associated 
with subsequent non-adherence.
A previous analysis of data from this study showed 
that patients’ beliefs about ART at treatment offer were 
strong predictors of subsequent non-adherence to ART. 
Specifically, patients who had strong concerns about ART 
and those who had doubts about their personal necessity 
for ART were more likely to be non-adherent during the 
subsequent year [12]. The findings of the current analysis 
show that medication beliefs also influence patients’ expe-
riences of symptoms attributed to medication side effects.
Our findings are consistent with those of previous stud-
ies in other long-term conditions, which found that patients 
who had negative expectations of treatment or stronger 
concerns about their medication were more likely to expe-
rience side effects [15, 16, 19]. To our knowledge only 
one previous study has examined the relationship between 
treatment concerns and side effect experiences in people 
living with HIV [14]. Gonzalez et al. found a significant 
association between medication beliefs and symptom 
reports, but were unable to determine the direction of the 
relationship due to the cross-sectional study design [14]. 
Through the use of a prospective, longitudinal design, the 
current study was able to ascertain that patients’ concerns 
about medicines before they started treatment predicted 
the subsequent reporting of ART side effects.
The association between depression and anxiety and 
experience of side effects is consistent with the findings of 
prospective studies of patients taking treatment for cancer 
and with people undergoing vaccination [16, 20]. The results 
of the mediational analysis conducted in the current study 
suggests that initiating treatment with strong concerns about 
ART may lead to depression and anxiety which in turn may 
impact on the experience of side effects. Further research, 
using a randomised controlled trial, will determine whether 
addressing ART concerns at baseline can reduce subsequent 
ART side effects, and whether depression and anxiety medi-
ate this effect.
Consistent with studies in other long-term conditions 
we found concerns about ART were influenced by patients’ 
beliefs about medicines in general, specifically beliefs that 
medicines are fundamentally harmful, addictive substances 
that should not be taken for long periods of time [21] and 
perceptions of personal sensitivity to adverse effects [21]. 
Other factors, such as the degree of trust that the patient has 
in their healthcare team have also been found to influence 
patients’ concerns about ART but were not measured in this 
study [13].
Limitations of the study included a low completion rate 
due to people stopping treatment, failing to return question-
naires and missing data in returned questionnaires. Those 
Table 4  Associations between 
baseline demographic, clinical 
and psychological variables and 
ART Concerns at baseline
r or rp p
Age r − 0.186 0.108
White British rp 0.024 0.834
Men who have sex with men (MSM) rp 0.067 0.563
Employed rp − 0.045 0.701
AIDS diagnosis rp − 0.062 0.592
Prior antiretroviral therapy (ART) rp 0.088 0.447
Protease-inhibitor based ART regimen rp − 0.077 0.508
CD4 count  (mm3/L) r 0.148 0.202
Viral load  (log10 copies/mL) r 0.088 0.450
Duration of HIV diagnosis (years) r 0.101 0.386
Beliefs about medicines questionnaire—general overuse r 0.054 0.677
Beliefs about medicines questionnaire-general harm r 0.298 0.019
Beliefs about medicines questionnaire—general benefits r − 0.162 0.211
Perceived sensitivity to medicines r 0.545 < 0.001
Hospital anxiety and depression scale—depression r 0.536 < 0.001
Hospital anxiety and depression scale—anxiety r 0.547 < 0.001
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with missing data were younger, more likely to have been 
previously prescribed ART and had more negative beliefs 
about medicines and higher depression and anxiety scores 
than those who provided complete data, all of which have 
been associated with low adherence [12]. The study sample 
may therefore over-represent patients who are highly adher-
ent to their treatment. Data were collected between 2000 
and 2004, since which time ART regimens have changed 
and are considerably better tolerated, therefore people tak-
ing ART are likely to report fewer side effects. Since 2004, 
there have also been changes to treatment guidelines [22], 
meaning that many people now start treatment at a much 
higher CD4 count than at the time of the study, and therefore 
may report fewer symptoms overall. As result of missing 
data, the study lacked power for multivariate statistics. It 
was therefore not possible to determine the relative effect of 
beliefs about medicines and other variables on the experi-
ence of side effects. Furthermore, the study was not suf-
ficiently powered to test the impact of the different ART 
regimens on side effect reports. It is likely that the profile of 
side effects reported by patients was affected by the medi-
cation they were taking and whether they changed medica-
tion over the course of the study. Larger datasets, allowing 
for the comparison of HIV side effect reports in different 
patient groups, would be needed to test whether the associa-
tions between beliefs, symptom reports and adherence seen 
within this study are consistent across different medication 
regimens. Multiple comparisons were made, increasing the 
possibility that one or more significant findings were due to 
chance (Type 1 error). We relied on self-report measures, 
including a self-report measure of adherence, which may be 
subject to a positive bias.
Conclusion
This study highlights the importance of patients’ pretreat-
ment beliefs about ART as determinants of their subsequent 
experience of side effects and nonadherence. Our findings 
are relevant to clinical practice and the design of interven-
tions to improve patients’ experiences of ART and promote 
adherence. They suggest that exploring and addressing 
patients’ concerns about ART before they initiate ART 
may prevent nonspecific side effects and improve patients’ 
experience of treatment. This, together with the continual 
development of new drugs that have fewer side effects, may 
improve patients’ experiences of ART and thereby facilitate 
adherence.
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